Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Treasury Shares (2023 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Treasury Shares for 3 consecutive years, with $744770.0 as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 105.74% to $744770.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $744770.0 through Dec 2025, up 105.74% year-over-year, with the annual reading at $744770.0 for FY2025, 105.74% up from the prior year.
  • Treasury Shares for Q4 2025 was $744770.0 at 4D Molecular Therapeutics, up from $698019.0 in the prior quarter.
  • The five-year high for Treasury Shares was $748380.0 in Q1 2025, with the low at $181181.0 in Q4 2023.
  • Average Treasury Shares over 3 years is $472903.6, with a median of $361997.0 recorded in 2024.
  • The sharpest move saw Treasury Shares surged 99.8% in 2024, then surged 256.54% in 2025.
  • Over 3 years, Treasury Shares stood at $181181.0 in 2023, then skyrocketed by 99.8% to $361997.0 in 2024, then surged by 105.74% to $744770.0 in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $744770.0, $698019.0, and $725101.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.